Compositions for treating vaginal infections with chronic inflammation

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a composition for local application for treating vaginitis of various origins and related inflammatory inflammations. The above composition contains benzophenanthridine alkaloids, benzofuran compounds and optionally Zanthoxylum bimgeanum or Echinacea angustifolia extract.

EFFECT: composition possesses antibacterial, antifungal and antienzymic activity and reduces vaginal infections fast, eliminates the presence of saprophytes, relieves inflammation, itch and vaginal pH.

12 cl, 3 tbl, 1 ex

 

SUMMARY of the INVENTION

The present invention relates to compositions containing compounds of benzofuran and benzophenantridin alkaloids, which have anti-inflammatory, antibacterial and antifungal activity, useful in the treatment of vaginal infections and the resulting inflammatory conditions.

PRIOR art

Often vaginitis initially has no symptoms, but over time can turn into a potentially dangerous infection. Vulvovaginal infections, whether viral, bacterial, fungal or protozoal origin (herpes, trichomoniasis, candidiasis), cause itching of the vulva, burning, irritation and damage, followed by external dysuria and vulvar dyspareunia. Vaginitis can lead to a number of serious events with recurrent infections such as toxic effects on other organs and apparatuses. This phenomenon is of particular importance in many developing countries, where these phenomena can lead to the patient the risk of HIV or other sexually transmitted diseases.

Trichomoniasis is manifested in the form of symptoms such as yellowish, purulent exudate and vulvar irritation, inflammation of the epithelium of the vulva and vagina, and petechial lesions of the cervix. The pH of the discharge exceeds 5, so that contributing to the development of Trichomonas. When Candida is severe itching of the vulva with erythema and edema, and allocation have an unpleasant odor, as in the case of bacterial vaginitis. These disorders are treated with oral antibiotics and antifungal agents that are injected in high doses or gels for topical treatment. These treatments always take a long time and can have side effects.

Benzophenantridin alkaloids isolated from Macleaya cordata, Macleaya microcarpa, Sanguinaria canadensis and Chelidonia majus particularly active against strains directly involved in vaginal infections such as Trichomonas vaginalis, Escherichia coli, Pseudomonas aeruginosa, etc.

According to the present invention compounds of benzofuran have the following formula

where R can represent hydrogen or alkyl linear or branched chain containing from 2 to 6 carbon atoms, or alkyl substituted amino group, a nitro-group; R preferably represents hydrogen or C1-C3.

These compounds benzofuran known and can be obtained by standard methods, for example by reaction of phenol, which appropriately substituted to obtain 2-phenoxy-2',4'-dimethoxyacetophenone in conditions that are described in Chimie Therapeutique 1973, 8, 398, followed cyclize what s in the presence of polyphosphoric acid in xylene and hydrolysis of methoxy - and hydroxy groups. Connection benzofuran used in the compositions according to the invention have the structural formula 1 and have powerful antibacterial and antifungal activity against many strains of Candida.

Description of the INVENTION

The present invention relates to compositions containing:

a) benzophenantridin alkaloids; and

b) compounds of benzofuran; and, optionally,

c) extract of Zanthoxylum bungeanum or Echinacea angustifolia, which have anti-inflammatory, antibacterial and antifungal activity and are useful for the treatment of vaginal infections and the resulting inflammatory conditions, in particular vaginitis different origin associated with inflammatory complications.

More specifically, the present invention relates to compositions containing:

a) benzophenantridin alkaloids, selected from sanguinarine and/or chelerythrine and/or derivatives thereof; and

b) compounds of benzofuran, as described above; and, optionally,

c) extract of Zanthoxylum bungeanum or Echinacea angustifolia.

It has been unexpectedly found that compositions according to the invention possess antibacterial, antifungal and antitermination activity that exceeds the sum of the activities of the various components when separate introduction. This effect may occur due to a synergistic mechanism is in action, which occurs between the various components of the considered complex. The composition of the invention to quickly eliminate these infections, excluding the presence of saprophytes and reducing inflammation, itching and vaginal pH.

The contents of the various components in the compositions according to the invention will be within the following limits by weight in a single dose):

a) benzophenantridin alkaloids: from 0.15 mg to 15 mg; and

b) compounds of benzofuran: from 0.2 to 25 mg; and, optionally,

c) extract of Zanthoxylum bungeanum or Echinacea angustifolia: from 0.1 to 10 mg.

In a particularly preferred aspect of the content of various components in the present compositions will be in the following intervals (by weight in a single dose):

a) benzophenantridin alkaloids: from 0.4 to 10 mg; and

b) compounds of benzofuran: from 0.4 to 10 mg; and, optionally,

c) extract of Zanthoxylum bungeanum or Echinacea angustifolia: from 0.2 to 5 mg.

Benzophenantridin alkaloids sanguinarine and chelerythrine may be present in free form or in salt form, as such, essentially in pure form or in the form of extracts of Sanguinaria canadensis, Macleaya cordata, Macleaya microcarpa or Chelidonia majus. In a preferred aspect benzophenantridin alkaloids will be present in salt form luteal acid. It is proved that these salts are obtained by reaction of sulphate or chloride alkaloi the s with sodium or potassium salt luteal acid and subsequent crystallization is particularly effective for the purposes of this invention. In particular, sanguinarine is a factor with potent antiangiogenic activity, which helps to reduce inflammation (Jong-Eun Pil 2004). Sanguinarine inhibits the formation of capillaries in Matrigel and in the chorioallantoic membrane of chicken embryo in vivo. (Jong-Eun Pil 2004).

These benzophenantridin alkaloids not only have significant antibacterial, antifungal and antitrichomonal activity, but also show significant activity against cytomegalovirus and human papillomavirus. For this reason, the archetypes of these alkaloids, sanguinarine, chelerythrine and chelidonine, which also have an analgesic effect, very effective for the treatment of vaginitis different etiology. Together, these compounds have a synergistic effect, which reduces inflammation and, thus, the symptoms, and also suppresses the disease.

Connection with the above benzofuranol structure may be present as such or in the form of the containing extracts, such as extracts of Krameria triandra, Eupomatia laurina and Piper sp. Proven especially active compounds isolated from Krameria triandra are automationid 6 and neolignans 2-(2,4-dihydroxyphenyl)-5-(E)-propenyl-benzofuran which exhibit antibacterial and antifungal activity against many strains of gram-positive bacteria, fungus is s and anaerobic bacteria.

In a particularly preferred aspect of the considered compositions also contain an extract of Zanthoxylum bungeanum or Echinacea angustifolia, which help eliminate itching and/or pain, if they are present. This action is possible because of the presence of isobutylamides that bind cannabioids receptor CB2 and CB1. The compositions according to the invention can be obtained in accordance with well known standard methods, such as those described in "Remington''s Pharmaceutical Handbook", Mack Publishing Co., N. Y., USA, together with suitable excipients.

The composition of the invention conveniently be in the form of emulsions, water/oil with other compatible excipients for topical use in the anogenital region; for use inside the data connection should be suspended in the oil in soft gelatin capsules that are easy to disintegrate after insertion into the vaginal opening.

Examples of compositions according to the invention include creams, ointments, powders, lotions, etc., vaginal pessaries or equivalent structures, including capsules that dissolve when the internal body temperature. The following examples illustrate the invention without limiting its scope.

Example 1 - Getting connection benzofuran

Stage A. Obtaining 2-phenoxy-2',4'-dimethoxyacetophenone (a)

A solution of 2-bromo-2',4'-dimethoxyacetophenone (5 g, of 19.1 mmol) in 25 ml of 2-bout the Nona was added to a suspension of phenol (1.8 g, of 19.1 mmol), K2CO3(2.6 g, 19,1 mmol) and KI (of 41.5 mg, 0.25 mmol) to 20.0 ml of the same solvent. Then the solution was boiled under reflux for 20 hours. The mixture was filtered, and the solvent was removed under vacuum. The obtained residue was dissolved in EtOAc and washed with 10% aqueous NaOH solution and then with water. The organic extract was dried over Na2SO4, filtered and evaporated under vacuum. In the end, the crude residue was washed Et2O and dried under reduced pressure to obtain 4.4 g (yield: 84%) specified in the connection header.

Stage B. Obtaining 2-(2',4'-acid)benzofuran (b)

12 g of polyphosphoric acid was added to a solution of compound obtained in stage A (4.4 g, 16.2 mmol), 130,0 ml of xylene. The mixture was boiled under reflux for 2 hours and then left to cool at ambient temperature. Then the solution decantation and evaporated under reduced pressure. The obtained residue (3.7 g, yield: 90%) was used in the next stage without additional purification.

Stage C. Obtaining 2-(2',4'-dihydroxyphenyl)benzofuran (1)

The mixture of compounds obtained in stage B (3.7 g, 14.5 mmol), and pyridine hydrochloride (11.1 g, 96,4 mmol) was heated to 225C for 45 minutes. The resulting red product was poured into 10% HCl. The mixture was washed several times EtOAc; the combined organic layers sushi and above Na 2SO4and evaporated. To highlight, the residue was purified column chromatography (hexane/EtOAc=7:3). After crystallization from benzene yield the final compound was 41% (1,36 g).

Example composition 1

Oily suspension for soft gelatin capsules for insertion into the vaginal opening

Lipophilic extract of Macleaya cordata (75%)10 mg
2,4-dihydroxyphenyl-3-benzofuran10 mg
Soy lecithin60 mg
Beeswax50 mg
Vegetable oil in sufficient quantities to800 mg

Example composition 2

Cream (emulsion oil-in-water")

Extract of Krameria triandra0.4 g
Fraction of alkaloids Macleaya cordata0.4 g
Lipophilic extract of Zanthoxylum bungeanum0.2 g
Propylene glycol10,00 g
Isopropylmyristate5,00 g
Cetyl alcohol5,00 g
Polysorbate 803.00 g
Carbomer0.40 g
Methyl parahydroxybenzoate0.10 g
Sodium propyl parahydroxybenzoate0.05 g
Vegetable oil in sufficient quantities to100 g

An example of a structure of 3

Vaginal pessary

2,4-dihydroxyphenyl-3-benzofuran10 mg
Fraction of alkaloids Macleaya3 mg
Glycerides of fatty acids in sufficient quantities to2.0 g

1. Composition for topical application for the treatment of vaginitis different origin and related inflammatory complications, containing:
a) benzophenantridin alkaloids; and
b) compounds of benzofuran formula

where R can represent hydrogen or alkyl with linear mud is branched chain, containing from 2 to 6 carbon atoms, or alkyl substituted amino group, a nitro-group; and, optionally,
c) extract of Zanthoxylum bungeanum or Echinacea angustifolia.

2. The composition according to claim 1, containing:
a) benzophenantridin alkaloids, selected from sanguinarine, chelerythrine or chelidonine, or their derivatives; and
b) compounds of benzofuran as specified in claim 1; and, optionally,
c) extract of Zanthoxylum bungeanum or Echinacea angustifolia.

3. The composition according to claim 1, where the content of the various components within the following intervals (by weight in a single dose):
a) benzophenantridin alkaloids: from 0.15 mg to 15 mg; and
b) compounds of benzofuran: from 0.2 to 25 mg; and, optionally,
c) extract of Zanthoxylum bungeanum or Echinacea angustifolia: from 0.1 to 10 mg.

4. The composition according to claim 2, where the contents of the various components within the following intervals (by weight in a single dose):
a) benzophenantridin alkaloids: from 0.15 to 15 mg; and
b) compounds of benzofuran: from 0.2 to 25 mg; and, optionally,
c) extract of Zanthoxylum bungeanum or Echinacea angustifolia: from 0.1 to 10 mg.

5. The composition according to claim 3, where the content of the various components within the following intervals (by weight in a single dose):
a) benzophenantridin alkaloids: from 0.4 to 10 mg; and/or
b) compounds of benzofuran: from 0.4 to 10 mg; and, optionally,
c) extract of Zanthoxylum bungeanum or Echinacea angustifolia: from 0.2 to 5 mg.

6. The composition according to claim 4, where sod is neigh various components within the following intervals (by weight in a single dose):
a) benzophenantridin alkaloids: from 0.4 to 10 mg; and
b) compounds of benzofuran: from 0.4 to 10 mg; and, optionally,
c) extract of Zanthoxylum bungeanum or Echinacea angustifolia: from 0.2 to 5 mg.

7. Composition according to any one of the preceding paragraphs, where benzophenantridin alkaloids sanguinarine and chelerythrine are present in free form or in salt form, as such, essentially, in pure form or in the form of extracts of Sanguinaria canadensis, Macleaya cordata, Macleaya microcarpa or Chelidonia majus.

8. The composition according to claim 7, where benzophenantridin alkaloids are present in salt form luteal acid.

9. The composition according to claims 1 to 6, where connections benzofuran present as such or in the form of the containing extracts.

10. The composition according to claim 9, where the connection benzofuran are present in the form of extracts of Krameria triandra, Eupomatia laurina and Piper sp.

11. The composition according to claim 1 in the form of emulsions, water/oil, soft gelatin capsules, vaginal pessaries or equivalent formulations, creams, ointments, powders, lotions.

12. Application:
a) benzophenantridin alkaloids; and
b) 2-(2,4-dihydroxyphenyl)-5-propenylbenzene (neolignans); and, optionally,
c) extract of Zanthoxylum bungeanum or Echinacea angustifolia for obtaining compositions for topical application for the treatment of vaginitis different origin and related inflammatory complications.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a composition for oral hygiene and for treating and preventing pathological conditions related to the dentofacial system, implants and complications following the oral surgeries. The above composition contains benzophenanthridine alkaloids, benzofuran compounds and catechine polyphenols.

EFFECT: composition possesses antibacterial, antifungal and antienzymic activity that exceeds total activities of the different ingredients if used separately.

14 cl, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gynaecology and may be used for individual selection of the preparations containing the probiotic lactic bacterial strains for effective intravaginal therapy. For this purpose, vaginal epithelial cells are recovered from the patient, released from the accompanying microflora. That is followed by preparing an epithelial cell suspension in a culture medium, and mixed with a suspension of thermally-activated probiotic lactic bacterial strains. Then, the suspension is incubated; the epithelial cell culture fluid filtrate is prepared and added to the suspension of the tested probiotic lactic bacterial strains in ratio 1:7. Concurrently, a reference of the mixture of the epithelial cell culture medium and the suspension of the tested probiotic lactic bacterial strains in ratio 1:7 is prepared. The test and reference samples are incubated, measured for optical density; and a degree of biomass increase in the test sample is related to that in the reference. The preparation containing the probiotic lactic bacterial strains the biomass increase of which under the influence of patient's vaginal epithelial cells is stimulated most is selected form the effective intravaginal therapy.

EFFECT: invention enables the individual selection of the preparations containing the probiotic lactic bacterial strains for the effective intravaginal therapy.

3 ex, 1 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine and is intended for treatment of vaginal infections. Method includes complex therapy with application of immunocorrector. As immunocorrector solution of medicine Betaleukin, introduced intravaginally during 40-90 minutes daily at least during 5 days, is applied.

EFFECT: method is highly efficient in complex therapy of vaginal infections.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to an agent for vaginal douche in the first phase of treatment of bacterial vaginosis. The agent for vaginal douche in the first phase of treatment for bacterial vaginosis, which represents a powder containing kitchen salt, citric acid, dry extract of chamomile (Matricaria chamomilla L) and sorbitol in the specific ingredient percentage.

EFFECT: agent allows reducing the length of the treatment of bacterial vaginosis and promotes normalising the natural vaginal flora.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to an agent for vaginal douche in the first phase of treatment of thrush (vaginal yeast). The agent for vaginal douche in the first phase of treatment for thrush (vaginal yeast), which represents a powder containing kitchen salt, baking powder and dry extract of chamomile (Matricaria chamomilla L) in the specific ingredient percentage.

EFFECT: agent is effective for vaginal douche in the first phase of treatment of thrush (vaginal yeast), eliminates the risk of a local allergic reaction.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to an agent for vaginal douche. The agent for vaginal douche in the phase of vaginal microflora recovery following the treatment of bacterial vaginosis, vaginal thrush (vaginal yeast) containing acetic acid sodium salt, lactose, dry extract of marigold (Calendula officinalis) in the following proportions.

EFFECT: agent promotes the effective recovery of a normal vaginal flora, provides hygienic cleaning of the vagina from its discharge and vaginal microorganisms during the procedure, eliminates the risk of local allergic reactions.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gynecology, endocrinology and can be used for correction of vaginal dysbiosis in case of metabolic syndrome. For this purpose complex impact on the organism by correction of body weight by means of no-pharmaceutical and pharmaceutical preparations is performed. Hypocaloric diet with reduced caloric content of 500-600 kcall/day, with reduced content of fats in food up to 20-30% and hypolipidemic direction is administered. Increased physical activity and xenical preparation are also administered for 6 months. Correction of metabolic disorders is carried out by means of preparations possessing antioxidant and membrane-stabilising action daily for 3 months. Recovery of vaginal microflora is performed by means of preliminary sanitation of vaginal biotope with antibacterial preparations for 7 days and immunocorrection for 10 days with further administration of eubiotic preparations for 5-7 days. Correction of vaginal dysbiosis is carried out until amount of opportunistic bacteria decreases and/or content of normal microflora is recovered.

EFFECT: method ensures increased efficiency of correction of dysbiotic vaginal disturbances in case of metabolic syndrome.

1 ex, 1 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is the use of oestriol for preparing a pharmaceutical composition for vaginal administration for preventing and/or treating urogenital atrophy due to estrogen deficiency in women, wherein said composition is administered so that the patient receives a dose of oestriol 0.3 mg/day or less with this administration being daily or once every two days, once every three days or once a week for at least 3 weeks and a related method for preventing and/or treating. It is shown that the administration of oestriol in a dose of 10 times less than the standard one; it eliminates the state of vaginal atrophy.

EFFECT: invention provides the therapeutic effectiveness similar to the responses to the modern methods of treating, but with greater safety leading to a better quality of life.

14 cl, 10 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is offered is a pharmaceutical composition for local application in gynaecology and containing therapeutically effective amounts of ornidazole, neomycin or gentamycin, an anti-inflammatory ingredient specified in a group of glucocorticosteroids, and an antimycotic ingredient specified in imidazole derivatives.

EFFECT: invention provides producing a new preparation for intravaginal therapy of infectious-inflammatory and disbiotic genital diseases in females.

5 cl, 8 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gynaecology, and represents a method for eliminating Atopobium vaginae bacteria in treating bacterial vaginosis characterised by using the Macmiror Complex preparation which in vaginally introduced in the form of one suppositorium once a day for seven-eight days.

EFFECT: invention provides effective treatment of bacterial vaginosis in recurrent forms of bacterial vaginosis, and also reduced length of treatment and eliminated recurrence after single therapeutic course.

5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a composition for oral hygiene and for treating and preventing pathological conditions related to the dentofacial system, implants and complications following the oral surgeries. The above composition contains benzophenanthridine alkaloids, benzofuran compounds and catechine polyphenols.

EFFECT: composition possesses antibacterial, antifungal and antienzymic activity that exceeds total activities of the different ingredients if used separately.

14 cl, 2 tbl, 1 ex

Iimmunomodulator // 2504371

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an immunomodulator. An immunomodulator for the immunocorrection accompanying the integrated treatment of chronic non-specific pulmonary diseases, chronic obstructive pulmonary disease, bronchial obstruction syndrome, chronic bronchial pneumonia, pulmonary fibrosis, tracheobronchitis, chronic laryngitis, pulmonary, tracheal and pharyngeal cancer; the immunomodulator is prepared by mixing a water infusion of rose bay leaves and a water infusion of yellow melilot taken in equal proportions, with a cattle lung and larynx powder, settling the prepared mixture, keeping on a boiling water bath, cooling; further, the mixture is filtered; the prepared solution is added with cattle blood serum containing leukaemia oncovirus antibodies, hemlock infusion, ascorbic and sorbic acids until all the ingredients fully dissolved; the prepared solution is placed in the water bath, cooled, filtered, sterilised under certain conditions.

EFFECT: above preparation provides higher effectiveness and reduces the length of treating the above diseases, and ensures the higher immunobiological properties of the human body.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutical industry and medicine, in particular, intended for treatment and care of oral cavity, which contains quantity of antioxidant, presenting ratio of extract weight to weight of antioxidant in range 1:1 to 5:1, and magnolia extract.

EFFECT: composition according to the claimed invention ensures enhanced antimicrobial action.

13 cl, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to cosmetology and represents regenerating composition for skin care which contains regulator pH-triethanolamine, BAA, base Salcare SC80, cyclomethicone DC345, preservative, odorant, water, which is characterised by the fact, that as biologically active additive it contains protein substance from quail egg and antioxidant, and base includes UV-filter, olive oil, glycerin, emulsifier Solubilisant LRL preservative Sharomix MCI an purified water, and components in composition are in specified ratio in wt %.

EFFECT: invention ensures moistening and protection of skin from ultraviolet irradiation, as well as, regeneration, increase of tone and elasticity of skin.

3 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to dentistry, and may be used for the local treatment and prevention of the primary dental pathologies in hemodialysis-dependent children suffering a terminal stage of the chronic renal failure. That is ensured by using a chewable substrate containing bee wax 4.0 g and cultivated angelica root 0.4 g 3 times a day for 15 minutes for 2 weeks.

EFFECT: method enables improving and stabilising the clinical measures of the active products of the oral fluid due to a synergetic effect of the substrate components.

4 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a combination of THCV or CBD and aripiprazole or an aripiprazole metabolite specified in dehydroaripiprazole, OPC-14857, DM-1458, DM-1451, DM-1452, DM-1454 or DCPP applicable for preventing or treating psychosis or a psychotic disorder wherein THCV or CBD are administered separately, sequentially or simultaneously with aripiprazole.

EFFECT: invention provides relieving or eliminating the undesirable side effects of aripiprazole or the aripiprazole metabolite, such as anxiety, catalepsy and ptosis.

11 cl, 5 ex, 18 tbl, 8 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetic industry and represents a cosmetic preparation containing water-dispersible polyurethane with linear main chains generally consisting of alternating hydrophilic and hydrophobic sections; herewith: a) both terminal sections (T) are hydrophibic and at least one of both sections (T) are a branched alkyl residue, b) a hydrophilic section (S) is attached to each section immediately (T), c) at least one hydrophobic section (D) is attached to at least one end of each section (S) immediately, and d) the main chain contains at least one hydrophilic section (P), if there are more than one sections (P) are provided, two sections (P) are divided by at least one hydrophobic section (D).

EFFECT: invention provides creating the cosmetic preparations having the improved viscosity maintained for longer periods of time.

9 cl, 13 ex, 4 tbl

Anti-wrinkle agents // 2503443

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents wrinkle-reducing agents containing compounds presented by general formula (1), stereoisomers or pharmacologically acceptable salts thereof, wherein R1 represents a hydrogen atom or a linear or branched alkyl group with 1-8 carbon atoms; R2 represents -SH, -SO3H, -S-X2, -SO-X3, -S02-X4, X2-X4 represents carbon atoms or aliphatic hydrocarbon groups with 1-8 carbon atoms independently, R3 represents a hydrogen atom or an acyl group with a linear or branched alkyl chain with 1-8 carbon atoms, R4 represents a phenyl, tolyl, ethyl phenyl, propyl phenyl, butyl phenyl, pentyl phenyl, hexyl phenyl, methoxyphenyl, ethoxyphenyl, propyl oxyphenyl, butyl oxyphenyl, pentyl oxyphenyl, hexyl oxyphenyl or biphenyl group, m is equal to 0, n is equal to the integer 1 or 2.

EFFECT: invention provides preparing the compounds and cosmetic products possessing the anti-wrinkle effectiveness.

10 cl, 11 ex, 2 tbl, 7 dwg

FIELD: medicine.

SUBSTANCE: invention refers to methods of treating early enamel loss. The presented method of treating or reducing early enamel caries involves the dental application of an effective amount of a dental composition wherein the dental composition has a main formulation containing dicalcium phosphate, wherein the dental composition additionally contains arginine in the free or salt form, and an effective amount of fluoride, wherein arginine is found in the amount of 2 to 10 wt % of total weight of the dental composition.

EFFECT: composition used in the method possess an ability to increase enamel demineralisation that enables treating or reducing early enamel caries.

3 cl, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to dentistry and may be used in the orthopaedic treatment of the patients with partial and/or complete denture defects using removable laminar dentures. A method involves making the removable laminar dentures, taking the oral hygienic measures, cleaning the removable laminar dentures. Ozonised olive oil is applied on an internal surface of the prosthetic basis that is followed by applying the prosthesis on the denture defect for 10-30 minutes. The prosthesis with ozonised olive oil applied on the internal surface of the basis is attached once a day for 8-16 days.

EFFECT: method provides more effective patient's adaptation to the removable laminar dentures due to the polycomponent mechanism of ozonised olive oil in the same environment with no negative side effects.

2 ex, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a composition for oral hygiene and for treating and preventing pathological conditions related to the dentofacial system, implants and complications following the oral surgeries. The above composition contains benzophenanthridine alkaloids, benzofuran compounds and catechine polyphenols.

EFFECT: composition possesses antibacterial, antifungal and antienzymic activity that exceeds total activities of the different ingredients if used separately.

14 cl, 2 tbl, 1 ex

Up!